Semaglutide API Impurity Triggers Launch Delay; Brokers Hold Ratings Amid Timeline Uncertainty

A manufacturing impurity in the semaglutide API forces a commercialisation pushout, disclosed on earnings call. Brokers maintain ratings but flag revenue deferral and regulatory scrutiny risk as key unknowns.

ndtv-profit-business · 7/10/2026, 6:06:05 AM · Ask about this →